Is metformin a GLP-1?

No. Metformin is a biguanide — an entirely different drug class from GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). They lower blood sugar by different mechanisms, are taken differently (metformin is a daily oral tablet, most GLP-1s are weekly injections), and produce very different amounts of weight loss. The confusion is understandable because both are used in type 2 diabetes and both can affect weight, but they are not the same category of drug.

Not really. Metformin works mainly in the liver, reducing how much glucose the liver releases, and improves how sensitive your tissues are to insulin. A GLP-1 receptor agonist mimics a gut hormone: it prompts insulin release when glucose is high, suppresses glucagon, slows how fast the stomach empties, and signals fullness in the brain. That appetite and satiety effect is why GLP-1s produce substantially more weight loss — metformin is not primarily an appetite drug.

The gap is large. Metformin produces modest weight change — typically a few pounds, and it is not FDA-approved for weight management at all. GLP-1 medications approved for weight management produce far more: in the only head-to-head trial of the two leading agents, tirzepatide averaged about 20% of body weight lost and semaglutide about 14% over 72 weeks. Anyone expecting metformin to do what a GLP-1 does will be disappointed, and anyone told it is "basically the same thing" has been misinformed.

Yes, and it is common — the combination is frequently the goal rather than a stepping stone, so metformin is usually continued when a GLP-1 is added. One practical point to agree with your prescriber in advance: metformin carries a boxed warning about lactic acidosis, and that risk rises with significant dehydration. GLP-1s can cause vomiting and diarrhea during dose escalation. Ask what to do about the metformin if you have a bad stretch, and when to call.

Dramatically. Metformin is an old generic and typically costs a few dollars a month; GLP-1 list prices run four figures. That price gap is the honest reason metformin is usually tried first in type 2 diabetes — not because the drugs are equivalent. If cost is your constraint, that is worth saying to your prescriber directly rather than assuming the cheaper drug will do the same job.

It has real evidence there, and it is worth knowing. In the landmark Diabetes Prevention Program trial, metformin cut progression to type 2 diabetes by about 31% over roughly three years — but an intensive lifestyle program cut it by about 58%, outperforming the drug. That is why structured prevention programs, not medication, are first-line in prediabetes, and why metformin remains a reasonable and inexpensive option within that.

The GLP-1 receptor agonists sold in the US are semaglutide (Ozempic and Rybelsus for type 2 diabetes, Wegovy for weight management), dulaglutide (Trulicity), and liraglutide (Saxenda for weight, Victoza for diabetes — Victoza was discontinued in 2024). Tirzepatide (Mounjaro, Zepbound) is a dual GIP and GLP-1 agonist, so it is related but acts on two receptors rather than one. Metformin is in none of these categories.